DAC linker is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-25. Numbers and descriptions here follow the published literature rather than marketing material.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Type II collagen is the basis for hyaline cartilage, including the articular cartilages at joint surfaces. It is formed by homotrimers of collagen, type II, alpha 1 chains. It makes up 50% of all protein in cartilage and 85–90% of collagen of articular cartilage. Type II collagen is organised into fibrils. This fibrillar network of collagen allows the cartilage to entrap the proteoglycan aggregate, as well as providing tensile strength to the tissue. Oral administration of native type II collagen induces oral tolerance to pathological immune responses and the administration of type II collagen tablets together with paracetamol might be more effective at reducing symptoms of osteoarthritis than paracetamol by itself.
=== Healing === It was believed that tendons could not undergo matrix turnover and that tenocytes were not capable of repair. However, it has since been shown that, throughout the lifetime of a person, tenocytes in the tendon actively synthesize matrix components as well as enzymes such as matrix metalloproteinases (MMPs) can degrade the matrix. Tendons are capable of healing and recovering from injuries in a process that is controlled by the tenocytes and their surrounding extracellular matrix. The three main stages of tendon healing are inflammation, repair or proliferation, and remodeling, which can be further divided into consolidation and maturation. These stages can overlap with each other. In the first stage, inflammatory cells such as neutrophils are recruited to the injury site, along with erythrocytes. Monocytes and macrophages are recruited within the first 24 hours, and phagocytosis of necrotic materials at the injury site occurs. After the release of vasoactive and chemotactic factors, angiogenesis and the proliferation of tenocytes are initiated. Tenocytes then move into the site and start to synthesize collagen III. After a few days, the repair or proliferation stage begins. In this stage, the tenocytes are involved in the synthesis of large amounts of collagen and proteoglycans at the site of injury, and the levels of GAG and water are high. After about six weeks, the remodeling stage begins. The first part of this stage is consolidation, which lasts from about six to ten weeks after the injury.
Flyorov is also known for the discovery of spontaneous fission with Konstantin Petrzhak. IUPAC approved the name in May, 2012 and the naming ceremony for flerovium and livermorium was held on 24 October 2012 in Moscow. Other proposals included atlantisium (An, a reference via Atlantis to the island of stability), lazarevium (Lz, in honor of Yuri Lazarev), and oganessium (Og, in honor of Yuri Oganessian). In a 2015 interview with Oganessian, the host, in preparation to ask a question, said, "You said you had dreamed to name [an element] after your teacher Georgy Flyorov." Without letting the host finish, Oganessian repeatedly said, "I did."
== Side effects and precautions == Since alpha-glucosidase inhibitors prevent the degradation of complex carbohydrates into glucose, the carbohydrates will remain in the intestine. In the colon, bacteria will digest the complex carbohydrates, thereby causing gastrointestinal side effects such as flatulence and diarrhea. Since these effects are dose-related, it is generally advised to start with a low dose and gradually increase the dose to the desired amount. Pneumatosis intestinalis is another reported side effect. If a patient using an alpha-glucosidase inhibitor suffers from an episode of hypoglycemia, the patient should eat something containing monosaccharides such as glucose tablets or a soft drink containing HFCS. Since the drug will prevent the digestion of polysaccharides (or non-monosaccharides), non-monosaccharide foods may not effectively reverse a hypoglycemic episode in a patient taking an alpha-glucosidase inhibitor.
==== Persecution of the Yemenite Jewish community ==== The Houthis have been accused of expelling or restricting members of the rural Yemeni Jewish community, which had about 50 remaining members. Reports of abuse include Houthi supporters bullying or attacking the country's Jews. Houthi officials have denied any involvement in the harassment, asserting that under Houthi control, Jews in Yemen would be able to live and operate freely as any other Yemeni citizen. "Our problems are with Zionism and the occupation of Palestine, but Jews here have nothing to fear," said Fadl Abu Taleb, a spokesman for the Houthis. Despite insistence by Houthi leaders that the movement is not sectarian, a Yemeni Jewish rabbi has reportedly said that many Jews remain terrified by the movement's slogan. As a result, Yemeni Jews reportedly retain a negative sentiment towards the Houthis, who they allege have committed persecutions against them. According to Israeli Druze politician Ayoob Kara, Houthi militants had given an ultimatum telling Jews to "convert to Islam or leave Yemen". In March 2016, a UAE-based newspaper reported that one of the Yemeni Jews who emigrated to Israel in 2016 was fighting with the Houthis. In the same month, a Kuwaiti newspaper, al-Watan, reported that a Yemeni Jew named Haroun al-Bouhi was killed in Najran while fighting with the Houthis against Saudi Arabia. The Kuwaiti newspaper added that the Yemeni Jews had a good relationship with Ali Abdullah Saleh, who was at that time allied with the Houthis and was fighting on different fronts with them.
Sources: en.wikipedia.org
Storage facilities need to be carefully designed to keep the potatoes alive and slow the natural process of sprouting which involves the breakdown of starch. It is crucial that the storage area be dark, ventilated well, and, for long-term storage, maintained at temperatures near 4 °C (39 °F). For short-term storage, temperatures of about 7 to 10 °C (45 to 50 °F) are preferred. Temperatures below 4 °C (39 °F) convert the starch in potatoes into sugar, which alters their taste and cooking qualities and leads to higher acrylamide levels in the cooked product, especially in deep-fried dishes. The discovery of acrylamides in starchy foods in 2002 has caused concern, but it is not likely that the acrylamides in food, even if it is somewhat burnt, causes cancer in humans. Chemicals are used to suppress sprouting of tubers during storage. Chlorpropham is the main chemical used, but it has been banned in the EU over toxicity concerns. Alternatives include ethylene, spearmint and orange oils, and 1,4-dimethylnaphthalene. Under optimum conditions in commercial warehouses, potatoes can be stored for up to 10–12 months. The commercial storage and retrieval of potatoes involves several phases: first drying surface moisture; wound healing at 85% to 95% relative humidity and temperatures below 25 °C (77 °F); a staged cooling phase; a holding phase; and a reconditioning phase, during which the tubers are slowly warmed. Mechanical ventilation is used at various points during the process to prevent condensation and the accumulation of carbon dioxide.
Tim Hortons reportedly had plans by 2013 to enter the large Indian market, which the company denied. In an effort to expand the company following its 2014 merger with Burger King into Restaurant Brands International, Tim Hortons began expansion in Asia in 2017 citing the increasing demand for coffee in large populations. The first Southeast Asian branch was opened in the Philippines on February 28, 2017, at Uptown Mall in Bonifacio Global City, Taguig. Siera Bearchell, Miss Universe Canada 2016, was present for the ribbon-cutting ceremony. As of December 2023, there are 52 locations operating in the Philippines.
A separate consequence is that the freshly milled particles carry high surface energy and acquire substantial triboelectric charge by repeated particle–wall and particle–particle contact during milling and downstream handling. The resulting electrostatic forces drive agglomeration, complicate blending uniformity, and — in dry powder inhaler formulations — cause drift in fine-particle fraction during storage as the powder relaxes toward thermodynamic equilibrium. To mitigate these effects, micronized actives intended for high-sensitivity applications are commonly subjected to a post-milling conditioning step, in which the powder is exposed to controlled humidity or a solvent vapour for hours to days to allow surface relaxation, partial recrystallization, and reduction of stored mechanical energy before formulation. Mechanical micronization is generally unsuitable for biologic APIs such as proteins, because the high-energy stresses of jet milling can cause denaturation; spray drying with stabilizing excipients is the route typically used to produce inhalable dry powders of biologics.
== Epidemiology == Hypoglycemia is common in people with type 1 diabetes, and in people with type 2 diabetes taking insulin, glinides, or sulfonylurea. It is estimated that type 1 diabetics experience two mild, symptomatic episodes of hypoglycemia per week. Additionally, people with type 1 diabetes have at least one severe hypoglyemic episode per year, requiring treatment assistance. In terms of mortality, hypoglycemia causes death in 6–10% of type 1 diabetics. In those with type 2 diabetes, hypoglycemia is less common compared to type 1 diabetics, because medications that treat type 2 diabetes like metformin, glitazones, alpha-glucosidase inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase IV inhibitors, do not cause hypoglycemia. Hypoglycemia is common in type 2 diabetics who take insulin, glinides, or sulfonylurea. Insulin use remains a key risk factor in developing hypoglycemia, regardless of diabetes type.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.